1. Home
  2. SER vs HYFT Comparison

SER vs HYFT Comparison

Compare SER & HYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

N/A

Current Price

$1.44

Market Cap

56.4M

Sector

Health Care

ML Signal

N/A

Logo MindWalk Holdings Corp.

HYFT

MindWalk Holdings Corp.

N/A

Current Price

$1.03

Market Cap

56.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SER
HYFT
Founded
2017
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.4M
56.5M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
SER
HYFT
Price
$1.44
$1.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
★ $9.50
$4.33
AVG Volume (30 Days)
71.2K
★ 252.1K
Earning Date
11-24-2026
12-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $130,000.00
N/A
Revenue This Year
N/A
$12.86
Revenue Next Year
N/A
$22.94
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 132.14
N/A
52 Week Low
$1.14
$0.98
52 Week High
$4.26
$3.00

Technical Indicators

Market Signals
Indicator
SER
HYFT
Relative Strength Index (RSI) 31.92 34.19
Support Level $1.38 N/A
Resistance Level $2.13 $1.50
Average True Range (ATR) 0.31 0.10
MACD -0.02 -0.01
Stochastic Oscillator 17.73 12.47

Price Performance

Historical Comparison
SER
HYFT

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

About HYFT MindWalk Holdings Corp.

MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

Share on Social Networks: